BRAF and neoplasm: From a clinical perspective, the combined evaluation of primary tumor location and this panel of candidate genomic alterations in RAS and BRAF wild-type patients may allow excluding a substantial proportion of resistant patients from EGFR inhibitors with meaningful predictive accuracy, thus representing a step forward in the way towards the optimization of the use of this therapeutic targeted approach.